Genetics of type 2 diabetes: Insights into the pathogenesis and its clinical application

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Sun, Xue ^a   Yu, Weihui ^b   Hu, Cheng ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ASIAN; DISEASE PREDISPOSITION; ETHNICITY; GENE LOCUS; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENETICS; HUMAN; LINKAGE ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PHARMACOGENOMICS; REVIEW; GENETIC PREDISPOSITION; PHARMACOGENETICS; RESEARCH; TRENDS;

DIABETES MELLITUS, TYPE 2; GENETIC LOCI; GENETIC PREDISPOSITION TO DISEASE; HUMANS; PHARMACOGENETICS; RESEARCH;

EID: 84900022532     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/926713     Document Type: Review

References (183)

1. Shaw J. E., Sicree R. A., Zimmet P. Z., Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Research and Clinical Practice 2010 87 1 4 14 2-s2.0-73749083481 10.1016/j.diabres.2009.10.007
2. Meigs J. B., Shrader P., Sullivan L. M., McAteer J. B., Fox C. S., Dupuis J., Manning A. K., Florez J. C., Wilson P. W. F., D'Agostino R. B. Sr., Cupples L. A., Genotype score in addition to common risk factors for prediction of type 2 diabetes. The New England Journal of Medicine 2008 359 21 2208 2219 2-s2.0-56749101779 10.1056/NEJMoa0804742
3. van Hoek M., Dehghan A., Witteman J. C. M., van Duijn C. M., Uitterlinden A. G., Oostra B. A., Hofman A., Sijbrands E. J. G., Janssens A. C. J. W., Predicting type 2 diabetes based on polymorphisms from genome-wide association studies: a population-based study. Diabetes 2008 57 11 3122 3128 2-s2.0-58149333712 10.2337/db08-0425
4. Cornelis M. C., Qi L., Zhang C., Kraft P., Manson J., Cai T., Hunter D. J., Hu F. B., Joint effects of common genetic variants on the risk for type 2 diabetes in US men and women of European ancestry. Annals of Internal Medicine 2009 150 8 541 550 2-s2.0-65349192772
5. Lyssenko V., Jonsson A., Almgren P., Pulizzi N., Isomaa B., Tuomi T., Berglund G., Altshuler D., Nilsson P., Groop L., Clinical risk factors, DNA variants, and the development of type 2 diabetes. The New England Journal of Medicine 2008 359 21 2220 2232 2-s2.0-55649105963 10.1056/NEJMoa0801869
6. Manolopoulos V. G., Ragia G., Tavridou A., Pharmacogenomics of oral antidiabetic medications: current data and pharmacoepigenomic perspective. Pharmacogenomics 2011 12 8 1161 1191 2-s2.0-80051766486 10.2217/pgs.11.65
7. Huang C., Florez J. C., Pharmacogenetics in type 2 diabetes: potential implications for clinical practice. Genome Medicine 2011 3 11, article 76 2-s2.0-82255186505 10.1186/gm292
8. Altshuler D., Hirschhorn J. N., Klannemark M., Lindgren C. M., Vohl M.-C., Nemesh J., Lane C. R., Schaffner S. F., Bolk S., Brewer C., Tuomi T., Gaudet D., Hudson T. J., Daly M., Groop L., Lander E. S., The common PPAR γ Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nature Genetics 2000 26 1 76 80 2-s2.0-0033624575 10.1038/79216
9. ATP channel subunits Kir6.2 (KCNJ11) and SUR1 (ABCC8) confirm that the KCNJ11 E23K variant is associated with type 2 diabetes. Diabetes 2003 52 2 568 572 2-s2.0-0037317981 10.2337/diabetes.52.2.568
10. Grant S. F. A., Thorleifsson G., Reynisdottir I., Benediktsson R., Manolescu A., Sainz J., Helgason A., Stefansson H., Emilsson V., Helgadottir A., Styrkarsdottir U., Magnusson K. P., Walters G. B., Palsdottir E., Jonsdottir T., Gudmundsdottir T., Gylfason A., Saemundsdottir J., Wilensky R. L., Reilly M. P., Rader D. J., Bagger Y., Christiansen C., Gudnason V., Sigurdsson G., Thorsteinsdottir U., Gulcher J. R., Kong A., Stefansson K., Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nature Genetics 2006 38 3 320 323 2-s2.0-32544451924 10.1038/ng1732
11. Sandhu M. S., Weedon M. N., Fawcett K. A., Wasson J., Debenham S. L., Daly A., Lango H., Frayling T. M., Neumann R. J., Sherva R., Blech I., Pharoah P. D., Palmer C. N. A., Kimber C., Tavendale R., Morris A. D., McCarthy M. I., Walker M., Hitman G., Glaser B., Permutt M. A., Hattersley A. T., Wareham N. J., Barroso I., Common variants in WFS1 confer risk of type 2 diabetes. Nature Genetics 2007 39 8 951 953 2-s2.0-34547536393 10.1038/ng2067
12. Gudmundsson J., Sulem P., Steinthorsdottir V., Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes. Nature Genetics 2007 39 8 977 983 10.1038/ng2062
13. Zeggini E., Weedon M. N., Lindgren C. M., Replication of genome-wide association signals in UK samples reveals risk loci for type 2 diabetes. Science 2007 316 5829 1336 1341
14. Saxena R., Voight B. F., Lyssenko V., Burtt N. P., de Bakker P. I. W., Chen H., Roix J. J., Kathiresan S., Hirschhorn J. N., Daly M. J., Hughes T. E., Groop L., Altshuler D., Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science 2007 316 5829 1331 1336 2-s2.0-34249888775 10.1126/science.1142358
15. Scott L. J., Mohlke K. L., Bonnycastle L. L., Willer C. J., Li Y., Duren W. L., Erdos M. R., Stringham H. M., Chines P. S., Jackson A. U., Prokunina-Olsson L., Ding C.-J., Swift A. J., Narisu N., Hu T., Pruim R., Xiao R., Li X.-Y., Conneely K. N., Riebow N. L., Sprau A. G., Tong M., White P. P., Hetrick K. N., Barnhart M. W., Bark C. W., Goldstein J. L., Watkins L., Xiang F., Saramies J., Buchanan T. A., Watanabe R. M., Valle T. T., Kinnunen L., Abecasis G. R., Pugh E. W., Doheny K. F., Bergman R. N., Tuomilehto J., Collins F. S., Boehnke M., A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants. Science 2007 316 5829 1341 1345 2-s2.0-34249885875 10.1126/science.1142382
16. Steinthorsdottir V., Thorleifsson G., Reynisdottir I., Benediktsson R., Jonsdottir T., Walters G. B., Styrkarsdottir U., Gretarsdottir S., Emilsson V., Ghosh S., Baker A., Snorradottir S., Bjarnason H., Ng M. C. Y., Hansen T., Bagger Y., Wilensky R. L., Reilly M. P., Adeyemo A., Chen Y., Zhou J., Gudnason V., Chen G., Huang H., Lashley K., Doumatey A., So W.-Y., Ma R. C. Y., Andersen G., Borch-Johnsen K., Jorgensen T., van Vliet-Ostaptchouk J. V., Hofker M. H., Wijmenga C., Christiansen C., Rader D. J., Rotimi C., Gurney M., Chan J. C. N., Pedersen O., Sigurdsson G., Gulcher J. R., Thorsteinsdottir U., Kong A., Stefansson K., A variant in CDKAL1 influences insulin response and risk of type 2 diabetes. Nature Genetics 2007 39 6 770 775 2-s2.0-34249828965 10.1038/ng2043
17. Sladek R., Rocheleau G., Rung J., Dina C., Shen L., Serre D., Boutin P., Vincent D., Belisle A., Hadjadj S., Balkau B., Heude B., Charpentier G., Hudson T. J., Montpetit A., Pshezhetsky A. V., Prentki M., Posner B. I., Balding D. J., Meyre D., Polychronakos C., Froguel P., A genome-wide association study identifies novel risk loci for type 2 diabetes. Nature 2007 445 7130 881 885 2-s2.0-33847176604 10.1038/nature05616
18. Burton P. R., Clayton D. G., Cardon L. R., Craddock N., Deloukas P., Duncanson A., Kwiatkowski D. P., McCarthy M. I., Ouwehand W. H., Samani N. J., Todd J. A., Donnelly P., Barrett J. C., Davison D., Easton D., Evans D., Leung H.-T., Marchini J. L., Morris A. P., Spencer C. C. A., Tobin M. D., Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 2007 447 7145 661 678 2-s2.0-34250025139 10.1038/nature05911
19. Zeggini E., Scott L. J., Saxena R., Voight B. F., Meta-analysis of genome-wide association data and large-scale replication identifies additional susceptibility loci for type 2 diabetes. Nature Genetics 2008 40 5 638 645 2-s2.0-42349106044 10.1038/ng.120
20. Bouatia-Naji N., Bonnefond A., Cavalcanti-Proença C., Sparsø T., Holmkvist J., Marchand M., Delplanque J., Lobbens S., Rocheleau G., Durand E., de Graeve F., Chèvre J.-C., Borch-Johnsen K., Hartikainen A.-L., Ruokonen A., Tichet J., Marre M., Weill J., Heude B., Tauber M., Lemaire K., Schuit F., Elliott P., Jørgensen T., Charpentier G., Hadjadj S., Cauchi S., Vaxillaire M., Sladek R., Visvikis-Siest S., Balkau B., Lévy-Marchal C., Pattou F., Meyre D., Blakemore A. I. F., Jarvelin M.-R., Walley A. J., Hansen T., Dina C., Pedersen O., Froguel P., A variant near MTNR1B is associated with increased fasting plasma glucose levels and type 2 diabetes risk. Nature Genetics 2009 41 1 89 94 2-s2.0-58149175143 10.1038/ng.277
21. Rung J., Cauchi S., Albrechtsen A., Shen L., Rocheleau G., Cavalcanti-Proença C., Bacot F., Balkau B., Belisle A., Borch-Johnsen K., Charpentier G., Dina C., Durand E., Elliott P., Hadjadj S., Järvelin M.-R., Laitinen J., Lauritzen T., Marre M., Mazur A., Meyre D., Montpetit A., Pisinger C., Posner B., Poulsen P., Pouta A., Prentki M., Ribel-Madsen R., Ruokonen A., Sandbaek A., Serre D., Tichet J., Vaxillaire M., Wojtaszewski J. F. P., Vaag A., Hansen T., Polychronakos C., Pedersen O., Froguel P., Sladek R., Genetic variant near IRS1 is associated with type 2 diabetes, insulin resistance and hyperinsulinemia. Nature Genetics 2009 41 10 1110 1115 2-s2.0-70349557826 10.1038/ng.443
22. Dupuis J., Langenberg C., Prokopenko I., New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nature Genetics 2010 42 2 105 116
23. Qi L., Cornelis M. C., Kraft P., Stanya K. J., Kao W. H. L., Pankow J. S., Dupuis J., Florez J. C., Fox C. S., Paré G., Sun Q., Girman C. J., Laurie C. C., Mirel D. B., Manolio T. A., Chasman D. I., Boerwinkle E., Ridker P. M., Hunter D. J., Meigs J. B., Lee C.-H., van Dam R. M., Hu F. B., Genetic variants at 2q24 are associated with susceptibility to type 2 diabetes. Human Molecular Genetics 2010 19 13 2706 2715 2-s2.0-77954172286 10.1093/hmg/ddq156
24. Voight B. F., Scott L. J., Steinthorsdottir V., Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis. Nature Genetics 2010 42 7 579 589 10.1038/ng.609
25. Morris A. P., Voight B. F., Teslovich T. M., Large-scale association analysis provides insights into the genetic architecture and pathophysiology of type 2 diabetes. Nature Genetics 2012 44 9 981 990 10.1038/ng.2383
26. Hu C., Wang C., Zhang R., Ma X., Wang J., Lu J., Qin W., Bao Y., Xiang K., Jia W., Variations in KCNQ1 are associated with type 2 diabetes and beta cell function in a Chinese population. Diabetologia 2009 52 7 1322 1325 2-s2.0-67349205597 10.1007/s00125-009-1335-6
27. Yamauchi T., Hara K., Maeda S., Yasuda K., Takahashi A., Horikoshi M., Nakamura M., Fujita H., Grarup N., Cauchi S., Ng D. P. K., Ma R. C. W., Tsunoda T., Kubo M., Watada H., Maegawa H., Okada-Iwabu M., Iwabu M., Shojima N., Shin H. D., Andersen G., Witte D. R., Jørgensen T., Lauritzen T., Sandbæk A., Hansen T., Ohshige T., Omori S., Saito I., Kaku K., Hirose H., So W.-Y., Beury D., Chan J. C. N., Park K. S., Tai E. S., Ito C., Tanaka Y., Kashiwagi A., Kawamori R., Kasuga M., Froguel P., Pedersen O., Kamatani N., Nakamura Y., Kadowaki T., A genome-wide association study in the Japanese population identifies susceptibility loci for type 2 diabetes at UBE2E2 and C2CD4A-C2CD4B. Nature Genetics 2010 42 10 864 868 2-s2.0-77957553197 10.1038/ng.660
28. Shu X. O., Long J., Cai Q., Identification of new genetic risk variants for type 2 diabetes. PLoS Genetics 2010 6 9 e1001127 10.1371/journal.pgen. 1001127
29. Tsai F.-J., Yang C.-F., Chen C.-C., Chuang L.-M., Lu C.-H., Chang C.-T., Wang T.-Y., Chen R.-H., Shiu C.-F., Liu Y.-M., Chang C.-C., Chen P., Chen C.-H., Fann C. S. J., Chen Y.-T., Wu J.-Y., A genome-wide association study identifies susceptibility variants for type 2 diabetes in Han Chinese. PLoS Genetics 2010 6 2 2-s2.0-77649214654 10.1371/journal.pgen.1000847 e1000847
30. Cho Y. S., Chen C. H., Hu C., Meta-analysis of genome-wide association studies identifies eight new loci for type 2 diabetes in east Asians. Nature Genetics 2012 44 1 67 72
31. Imamura M., Maeda S., Yamauchi T., A single-nucleotide polymorphism in ANK1 is associated with susceptibility to type 2 diabetes in Japanese populations. Human Molecular Genetics 2012 21 13 3042 3049 10.1093/hmg/dds113
32. Li H., Gan W., Lu L., A genome-wide association study identifies GRK5 and RASGRP1 as type 2 diabetes loci in Chinese Hans. Diabetes 2013 62 1 291 298 10.2337/db12-0454
33. Ma R. C., Hu C., Tam C. H., Genome-wide association study in a Chinese population identifies a susceptibility locus for type 2 diabetes at 7q32 near PAX4. Diabetologia 2013 56 6 1291 1305
34. Hara K., Fujita H., Johnson T. A., Genome-wide association study identifies three novel loci for type 2 diabetes. Human Molecular Genetics 2014 23 1 239 246 10.1093/hmg/ddt399
35. Kooner J. S., Saleheen D., Sim X., Genome-wide association study in individuals of South Asian ancestry identifies six new type 2 diabetes susceptibility loci. Nature Genetics 2011 43 10 984 989 10.1038/ng.921
36. Tabassum R., Chauhan G., Dwivedi O. P., Genome-wide association study for type 2 diabetes in Indians identifies a new susceptibility locus at 2q21. Diabetes 2013 62 3 977 986 10.2337/db12-0406
37. Saxena R., Saleheen D., Been L. F., Genome-wide association study identifies a novel locus contributing to type 2 diabetes susceptibility in Sikhs of Punjabi origin from India. Diabetes 2013 62 5 1746 1755 10.2337/db12-1077
38. Fajans S. S., Bell G. I., Polonsky K. S., Molecular mechanisms and clinical pathophysiology of maturity-onset diabetes of the young. The New England Journal of Medicine 2001 345 13 971 980 2-s2.0-0035960122 10.1056/NEJMra002168
39. Barroso I., Genetics of type 2 diabetes. Diabetic Medicine 2005 22 5 517 535 2-s2.0-17844373857 10.1111/j.1464-5491.2005.01550.x
40. Vaxillaire M., Froguel P., Monogenic diabetes in the young, pharmacogenetics and relevance to multifactorial forms of type 2 diabetes. Endocrine Reviews 2008 29 3 254 264 2-s2.0-43549084587 10.1210/er.2007-0024
41. Horikawa Y., Oda N., Cox N. J., Genetic variation in the gene encoding calpain-10 is associated with type 2 diabetes mellitus. Nature Genetics 2000 26 2 163 175 10.1038/79876
42. Meyre D., Bouatia-Naji N., Tounian A., Samson C., Lecoeur C., Vatin V., Ghoussaini M., Wachter C., Hercberg S., Charpentier G., Patsch W., Pattou F., Charles M.-A., Tounian P., Clément K., Jouret B., Weill J., Maddux B. A., Goldfine I. D., Walley A., Boutin P., Dina C., Froguel P., Variants of ENPP1 are associated with childhood and adult obesity and increase the risk of glucose intolerance and type 2 diabetes. Nature Genetics 2005 37 8 863 867 2-s2.0-23044493861 10.1038/ng1604
43. Love-Gregory L. D., Wasson J., Ma J., Jin C. H., Glaser B., Suarez B. K., Permutt M. A., A common polymorphism in the upstream promoter region of the hepatocyte nuclear factor-4 α gene on chromosome 20 q is associated with type 2 diabetes and appears to contribute to the evidence for linkage in an Ashkenazi Jewish population. Diabetes 2004 53 4 1134 1140 2-s2.0-1842422877 10.2337/diabetes.53.4.1134
44. Silander K., Mohlke K. L., Scott L. J., Peck E. C., Hollstein P., Skol A. D., Jackson A. U., Delonkas P., Hunt S., Stavrides G., Chines P. S., Erdos M. R., Narisu N., Conneely K. N., Li C., Fingerlin T. E., Dhanjal S. K., Valle T. T., Bergman R. N., Tuomilehto J., Watanabe R. M., Boehnke M., Collins F. S., Genetic variation near the hepatocyte nuclear factor-4 α gene predicts susceptibility to type 2 diabetes. Diabetes 2004 53 4 1141 1149 2-s2.0-12144291217 10.2337/diabetes.53.4.1141
45. Vasseur F., Helbecque N., Dina C., Lobbens S., Delannoy V., Gaget S., Boutin P., Vaxillaire M., Leprêtre F., Dupont S., Hara K., Clément K., Bihain B., Kadowaki T., Froguel P., Single-nucleotide polymorphism haplotypes in the both proximal promoter and exon 3 of the APM1 gene modulate adipocyte-secreted adiponectin hormone levels and contribute to the genetic risk for type 2 diabetes in French Caucasians. Human Molecular Genetics 2002 11 21 2607 2614 2-s2.0-18644369745 10.1093/hmg/11.21.2607
46. Deeb S. S., Fajas L., Nemoto M., Pihlajamäki J., Mykkänen L., Kuusisto J., Laakso M., Fujimoto W., Auwerx J., A Pro12Ala substitution in PPAR γ 2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nature Genetics 1998 20 3 284 287 2-s2.0-0031595923 10.1038/3099
47. Karasik A., O'Hara C., Srikanta S., Swift M., Soeldner J. S., Kahn C. R., Herskowitz R. D., Genetically programmed selective islet β -cell loss in diabetic subjects with Wolfram's syndrome. Diabetes Care 1989 12 2 135 138 2-s2.0-0024599929
48. Riggs A. C., Bernal-Mizrachi E., Ohsugi M., Wasson J., Fatrai S., Welling C., Murray J., Schmidt R. E., Herrera P. L., Permutt M. A., Mice conditionally lacking the Wolfram gene in pancreatic islet beta cells exhibit diabetes as a result of enhanced endoplasmic reticulum stress and apoptosis. Diabetologia 2005 48 11 2313 2321 2-s2.0-27744523525 10.1007/s00125-005-1947-4
49. Yamada T., Ishihara H., Tamura A., Takahashi R., Yamaguchi S., Takei D., Tokita A., Satake C., Tashiro F., Katagiri H., Aburatani H., Miyazaki J.-I., Oka Y., WFS1 -deficiency increases endoplasmic reticulum stress, impairs cell cycle progression and triggers the apoptotic pathway specifically in pancreatic β -cells. Human Molecular Genetics 2006 15 10 1600 1609 2-s2.0-33745202552 10.1093/hmg/ddl081
50. Groves C. J., Zeggini E., Minton J., Frayling T. M., Weedon M. N., Rayner N. W., Hitman G. A., Walker M., Wiltshire S., Hattersley A. T., McCarthy M. I., Association analysis of 6,736 UK subjects provides replication and confirms TCF7L2 as a type 2 diabetes susceptibility gene with a substantial effect on individual risk. Diabetes 2006 55 9 2640 2644 2-s2.0-33750602980 10.2337/db06-0355
51. Zhang C., Qi L., Hunter D. J., Meigs J. B., Manson J. E., Van Dam R. M., Hu F. B., Variant of transcription factor 7-like 2 (TCF7L2) gene and the risk of type 2 diabetes in large cohorts of US women and men. Diabetes 2006 55 9 2645 2648 2-s2.0-33750594321 10.2337/db06-0643
52. Scott L. J., Bonnycastle L. L., Willer C. J., Sprau A. G., Jackson A. U., Narisu N., Duren W. L., Chines P. S., Stringham H. M., Erdos M. R., Valle T. T., Tuomilehto J., Bergman R. N., Mohlke K. L., Collins F. S., Boehnke M., Association of transcription factor 7-like 2 (TCF7L2) variants with type 2 diabetes in a Finnish sample. Diabetes 2006 55 9 2649 2653 2-s2.0-33750587754 10.2337/db06-0341
53. Damcott C. M., Pollin T. I., Reinhart L. J., Ott S. H., Shen H., Silver K. D., Mitchell B. D., Shuldiner A. R., Polymorphisms in the transcription factor 7-like 2 (TCF7L2) gene are associated with type 2 diabetes in the Amish: replication and evidence for a role in both insulin secretion and insulin resistance. Diabetes 2006 55 9 2654 2659 2-s2.0-33750584981 10.2337/db06-0338
54. Saxena R., Gianniny L., Burtt N. P., Lyssenko V., Giuducci C., Sjögren M., Florez J. C., Almgren P., Isomaa B., Orho-Melander M., Lindblad U., Daly M. J., Tuomi T., Hirschhorn J. N., Ardlie K. G., Groop L. C., Altshuler D., Common single nucleotide polymorphisms in TCF7L2 are reproducibly associated with type 2 diabetes and reduce the insulin response to glucose in nondiabetic individuals. Diabetes 2006 55 10 2890 2895 2-s2.0-33750892139 10.2337/db06-0381
55. Cauchi S., Meyre D., Dina C., Choquet H., Samson C., Gallina S., Balkau B., Charpentier G., Pattou F., Stetsyuk V., Scharfmann R., Staels B., Frühbeck G., Froguel P., Transcription factor TCF7L2 genetic study in the French population: expression in human β -cells and adipose tissue and strong association with type 2 diabetes. Diabetes 2006 55 10 2903 2908 2-s2.0-33750889376 10.2337/db06-0474
56. Hayashi T., Iwamoto Y., Kaku K., Hirose H., Maeda S., Replication study for the association of TCF7L2 with susceptibility to type 2 diabetes in a Japanese population. Diabetologia 2007 50 5 980 984 2-s2.0-34147119644 10.1007/s00125-007-0618-z
57. Horikoshi M., Hara K., Ito C., Nagai R., Froguel P., Kadowaki T., A genetic variation of the transcription factor 7-like 2 gene is associated with risk of type 2 diabetes in the Japanese population. Diabetologia 2007 50 4 747 751 2-s2.0-33847618213 10.1007/s00125-006-0588-6
58. Foley A. C., Mercola M., Heart induction by Wnt antagonists depends on the homeodomain transcription factor Hex. Genes & Development 2005 19 3 387 396 2-s2.0-13244291649 10.1101/gad.1279405
59. Simonis-Bik A. M., Nijpels G., van Haeften T. W., Houwing-Duistermaat J. J., Boomsma D. I., Reiling E., van Hove E. C., Diamant M., Kramer M. H. H., Heine R. J., Maassen J. A., Slagboom P. E., Willemsen G., Dekker J. M., Eekhoff E. M., de Geus E. J., 'T Hart L. M., Gene variants in the novel type 2 diabetes loci CDC123 / CAMK1D, THADA, ADAMTS9, BCL11A, and MTNR1B affect different aspects of pancreatic β -cell function. Diabetes 2010 59 1 293 301 2-s2.0-76749093118 10.2337/db09-1048
60. Grarup N., Andersen G., Krarup N. T., Albrechtsen A., Schmitz O., Joørgensen T., Borch-Johnsen K., Hansen T., Pedersen O., Association testing of novel type 2 diabetes risk alleles in the JAZF1, CDC123 / CAMK1D, TSPAN8, THADA, ADAMTS9, and NOTCH2 Loci with insulin release, insulin sensitivity, and obesity in a population-based sample of 4,516 glucose-tolerant middle-aged danes. Diabetes 2008 57 9 2534 2540 2-s2.0-50049119989 10.2337/db08-0436
61. Prokopenko I., Langenberg C., Florez J. C., Variants in MTNR1B influence fasting glucose levels. Nature Genetics 2009 41 1 77 81 10.1038/ng.290
62. 3 family with a novel HNF1A germline mutation. Journal of Hepatology 2013 59 4 904 907 10.1016/j.jhep.2013.05.024
63. Lim D. M., Huh N., Park K. Y., Hepatocyte nuclear factor 1- α mutation in normal glucose-tolerant subjects and early-onset type 2 diabetic patients. Korean Journal of Internal Medicine 2008 23 4 165 169 2-s2.0-63249116231 10.3904/kjim.2008.23.4.165
64. Hegele R. A., Cao H., Harris S. B., Hanley A. J. G., Zinman B., The hepatic nuclear factor-1 α G319S variant is associated with early-onset type 2 diabetes in Canadian Oji-Cree. The Journal of Clinical Endocrinology & Metabolism 1999 84 3 1077 1082 2-s2.0-0033027001
65. Xu H., Dembski M., Yang Q., Yang D., Moriarty A., Tayber O., Chen H., Kapeller R., Tartaglia L. A., Dual specificity mitogen-activated protein (MAP) kinase phosphatase-4 plays a potential role in insulin resistance. The Journal of Biological Chemistry 2003 278 32 30187 30192 2-s2.0-0042530516 10.1074/jbc.M302010200
66. Bazuine M., Carlotti F., Tafrechi R. S., Hoeben R. C., Maassen J. A., Mitogen-activated protein kinase (MAPK) phosphatase-1 and -4 attenuate p38 MAPK during dexamethasone-induced insulin resistance in 3T3-L1 adipocytes. Molecular Endocrinology 2004 18 7 1697 1707 2-s2.0-3042836359 10.1210/me.2003-0213
67. Emanuelli B., Eberlé D., Suzuki R., Kahn C. R., Overexpression of the dual-specificity phosphatase MKP-4/DUSP-9 protects against stress-induced insulin resistance. Proceedings of the National Academy of Sciences of the United States of America 2008 105 9 3545 3550 2-s2.0-42149155999 10.1073/pnas.0712275105
68. Harder M. N., Ribel-Madsen R., Justesen J. M., Type 2 diabetes risk alleles near BCAR1 and in ANK1 associate with decreased β -cell function whereas risk alleles near ANKRD55 and GRB14 associate with decreased insulin sensitivity in the Danish Inter99 cohort. The Journal of Clinical Endocrinology & Metabolism 2013 98 4 E801 E806 10.1210/jc.2012-4169
69. Li H., Oldenburg B., Chamberlain C., Diabetes prevalence and determinants in adults in China mainland from 2000 to 2010: a systematic review. Diabetes Research and Clinical Practice 2012 98 2 226 235 10.1016/j.diabres.2012.05.010
70. Yasuda K., Miyake K., Horikawa Y., Variants in KCNQ1 are associated with susceptibility to type 2 diabetes mellitus. Nature Genetics 2008 40 9 1092 1097 10.1038/ng.207
71. Unoki H., Takahashi A., Kawaguchi T., Hara K., Horikoshi M., Andersen G., Ng D. P. K., Holmkvist J., Borch-Johnsen K., Jørgensen T., Sandbæk A., Lauritzen T., Hansen T., Nurbaya S., Tsunoda T., Kubo M., Babazono T., Hirose H., Hayashi M., Iwamoto Y., Kashiwagi A., Kaku K., Kawamori R., Tai E. S., Pedersen O., Kamatani N., Kadowaki T., Kikkawa R., Nakamura Y., Maeda S., SNPs in KCNQ1 are associated with susceptibility to type 2 diabetes in East Asian and European populations. Nature Genetics 2008 40 9 1098 1102 2-s2.0-50449085212 10.1038/ng.208
72. Lee Y.-H., Kang E. S., Kim S. H., Han S. J., Kim C. H., Kim H. J., Ahn C. W., Cha B. S., Nam M., Nam C. M., Lee H. C., Association between polymorphisms in SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1, KCNQ1 and type 2 diabetes in the Korean population. Journal of Human Genetics 2008 53 11-12 991 998 2-s2.0-57349191471 10.1007/s10038-008-0341-8
73. Tan J. T., Nurbaya S., Gardner D., Ye S., Tai E. S., Ng D. P. K., Genetic variation in KCNQ1 associates with fasting glucose and β -cell function: a study of 3,734 subjects comprising three ethnicities living in Singapore. Diabetes 2009 58 6 1445 1449 2-s2.0-66649101376 10.2337/db08-1138
74. Müssig K., Staiger H., Machicao F., Kirchhoff K., Guthoff M., Schäfer S. A., Kantartzis K., Silbernagel G., Stefan N., Holst J. J., Gallwitz B., Häring H.-U., Fritsche A., Association of type 2 diabetes candidate polymorphisms in KCNQ1 with incretin and insulin secretion. Diabetes 2009 58 7 1715 1720 2-s2.0-67650251656 10.2337/db08-1589
75. Chang Y. C., Chiu Y. F., Liu P. H., Replication of genome-wide association signals of type 2 diabetes in Han Chinese in a prospective cohort. Clinical Endocrinology 2012 76 3 365 372 10.1111/j.1365-2265.2011.04175.x
76. Wolosker H., Blackshaw S., Snyder S. H., Serine racemase: a glial enzyme synthesizing D-serine to regulate glutamate- N -methyl-D-aspartate neurotransmission. Proceedings of the National Academy of Sciences of the United States of America 1999 96 23 13409 13414 2-s2.0-0033539510 10.1073/pnas.96.23. 13409
77. Wolosker H., Sheth K. N., Takahashi M., Mothet J.-P., Brady R.O. J., Ferris C. D., Snyder S. H., Purification of serine racemase: biosynthesis of the neuromodulator D-serine. Proceedings of the National Academy of Sciences of the United States of America 1999 96 2 721 725 2-s2.0-0033582230 10.1073/pnas.96.2.721
78. 1C levels via glycemic and nonglycemic pathways. Diabetes 2010 59 12 3229 3239 10.2337/db10-0502
79. Wang L., Shen M., Wang F., GRK5 ablation contributes to insulin resistance. Biochemical and Biophysical Research Communications 2012 429 1-2 99 104 10.1016/j.bbrc.2012.10.077
80. Wang J., Elghazi L., Parker S. E., Kizilocak H., Asano M., Sussel L., Sosa-Pineda B., The concerted activities of PAX4 and Nkx2.2 are essential to initiate pancreatic β -cell differentiation. Developmental Biology 2004 266 1 178 189 2-s2.0-0347722280 10.1016/j.ydbio.2003.10.018
81. Zhang Y., Proenca R., Maffei M., Barone M., Leopold L., Friedman J. M., Positional cloning of the mouse obese gene and its human homologue. Nature 1994 372 6505 425 432 2-s2.0-0028139089 10.1038/372425a0
82. Liu Y., Yu L., Zhang D., Chen Z., Zhou D. Z., Zhao T., Li S., Wang T., Hu X., Feng G. Y., Zhang Z. F., He L., Xu H., Positive association between variations in CDKAL1 and type 2 diabetes in Han Chinese individuals. Diabetologia 2008 51 11 2134 2137 2-s2.0-53549096229 10.1007/s00125-008-1141-6
83. Xu M., Bi Y., Xu Y., Yu B., Huang Y., Gu L., Wu Y., Zhu X., Li M., Wang T., Song A., Hou J., Li X., Ning G., Combined effects of 19 common variations on type 2 diabetes in Chinese: results from two community-based studies. PLoS ONE 2010 5 11 2-s2.0-78649526616 10.1371/journal.pone.0014022 e14022
84. Wu Y., Li H., Loos R. J. F., Yu Z., Ye X., Chen L., Pan A., Hu F. B., Lin X., Common variants in CDKAL1, CDKN2A/B, IGF2BP2, SLC30A8, and HHEX/IDE genes are associated with type 2 diabetes and impaired fasting glucose in a Chinese Han population. Diabetes 2008 57 10 2834 2842 2-s2.0-56349170898 10.2337/db08-0047
85. Liu Y., Liu Z., Song Y., Zhou D., Zhang D., Zhao T., Chen Z., Yu L., Yang Y., Feng G., Li J., Zhang J., Liu S., Zhang Z., He L., Xu H., Meta-analysis added power to identify variants in FTO associated with type 2 diabetes and obesity in the Asian population. Obesity 2010 18 8 1619 1624 2-s2.0-77955051399 10.1038/oby.2009.469
86. Wen J., Rönn T., Olsson A., Yang Z., Lu B., Du Y., Groop L., Ling C., Hu R., Investigation of type 2 diabetes risk alleles support CDKN2A/B, CDKAL1, and TCF7L2 as susceptibility genes in a Han Chinese cohort. PLoS ONE 2010 5 2 2-s2.0-77949346987 10.1371/journal.pone.0009153 e9153
87. Hu C., Zhang R., Wang C., Wang J., Ma X., Lu J., Qin W., Hou X., Wang C., Bao Y., Xiang K., Jia W., PPARG, KCNJ11, CDKAL1, CDKN2A-CDKN2B, IDE-KIF11-HHEX, IGF2BP2 and SLC30A8 are associated with type 2 diabetes in a chinese population. PLoS ONE 2009 4 10 2-s2.0-70449433016 10.1371/journal.pone.0007643 e7643
88. Xiang J., Li X.-Y., Xu M., Hong J., Huang Y., Tan J.-R., Lu X., Dai M., Yu B., Ning G., Zinc transporter-8 gene (SLC30A8) is associated with type 2 diabetes in Chinese. The Journal of Clinical Endocrinology & Metabolism 2008 93 10 4107 4112 2-s2.0-53749086159 10.1210/jc.2008-0161
89. Rönn T., Wen J., Yang Z., Lu B., Du Y., Groop L., Hu R., Ling C., A common variant in MTNR1B, encoding melatonin receptor 1B, is associated with type 2 diabetes and fasting plasma glucose in Han Chinese individuals. Diabetologia 2009 52 5 830 833 2-s2.0-64149094603 10.1007/s00125-009-1297-8
90. Ng M. C. Y., Tam C. H. T., Lam V. K. L., So W.-Y., Ma R. C. W., Chan J. C. N., Replication and identification of novel variants at TCF7L2 associated with type 2 diabetes in Hong Kong Chinese. The Journal of Clinical Endocrinology & Metabolism 2007 92 9 3733 3737 2-s2.0-34548765645 10.1210/jc.2007-0849
91. Ng M. C. Y., Park K. S., Oh B., Tam C. H. T., Cho Y. M., Shin H. D., Lam V. K. L., Ma R. C. W., So W. Y., Cho Y. S., Kim H.-L., Lee H. K., Chan J. C. N., Cho N. H., Implication of genetic variants near TCF7L2, SLC30A8, HHEX, CDKAL1, CDKN2A/B, IGF2BP2, and FTO in type 2 diabetes and obesity in 6,719 Asians. Diabetes 2008 57 8 2226 2233 2-s2.0-50449104632 10.2337/db07-1583
92. Chang Y.-C., Chang T.-J., Jiang Y.-D., Kuo S.-S., Lee K.-C., Chiu K. C., Chuang L.-M., Association study of the genetic polymorphisms of the transcription factor 7-like 2 (TCF7L2) gene and type 2 diabetes in the Chinese population. Diabetes 2007 56 10 2631 2637 2-s2.0-34948845069 10.2337/db07-0421
93. Fukuda H., Imamura M., Tanaka Y., A single nucleotide polymorphism within DUSP9 is associated with susceptibility to type 2 diabetes in a Japanese population. PLoS One 2012 7 9 10.1371/journal.pone.0046263 e46263
94. Basnyat B., Rajapaksa L. C., Cardiovascular and infectious diseases in South Asia: the double whammy. British Medical Journal 2004 328 7443 781 2-s2.0-1842558762 10.1136/bmj.328.7443.781
95. Anjana R. M., Pradeepa R., Deepa M., Datta M., Sudha V., Unnikrishnan R., Bhansali A., Joshi S. R., Joshi P. P., Yajnik C. S., Dhandhania V. K., Nath L. M., Das A. K., Rao P. V., Madhu S. V., Shukla D. K., Kaur T., Priya M., Nirmal E., Parvathi S. J., Subhashini S., Subashini R., Ali M. K., Mohan V., Prevalence of diabetes and prediabetes (impaired fasting glucose and/or impaired glucose tolerance) in urban and rural India: phase i results of the Indian Council of Medical Research-INdia DIABetes (ICMR-INDIAB) study. Diabetologia 2011 54 12 3022 3027 2-s2.0-82455212116 10.1007/s00125-011-2291-5
96. Ramachandran A., Ma R. C., Snehalatha C., Diabetes in Asia. The Lancet 2010 375 9712 408 418 2-s2.0-75149176607 10.1016/S0140-6736(09)60937-5
97. Chambers J. C., Obeid O. A., Refsum H., Ueland P., Hackett D., Hooper J., Turner R. M., Thompson S. G., Kooner J. S., Plasma homocysteine concentrations and risk of coronary heart disease in UK Indian Asian and European men. The Lancet 2000 355 9203 523 527 2-s2.0-0034639623
98. Sanghera D. K., Ortega L., Han S., Singh J., Ralhan S. K., Wander G. S., Mehra N. K., Mulvihill J. J., Ferrell R. E., Nath S. K., Kamboh M. I., Impact of nine common type 2 diabetes risk polymorphisms in Asian Indian Sikhs: PPARG2 (Pro12Ala), IGF2BP2, TCF7L2 and FTO variants confer a significant risk. BMC Medical Genetics 2008 9, article 59 2-s2.0-47749128415 10.1186/1471-2350-9-59
99. Yajnik C. S., Janipalli C. S., Bhaskar S., Kulkarni S. R., Freathy R. M., Prakash S., Mani K. R., Weedon M. N., Kale S. D., Deshpande J., Krishnaveni G. V., Veena S. R., Fall C. H. D., McCarthy M. I., Frayling T. M., Hattersley A. T., Chandak G. R., FTO gene variants are strongly associated with type 2 diabetes in South Asian Indians. Diabetologia 2009 52 2 247 252 2-s2.0-58149470594 10.1007/s00125-008-1186-6
100. Chidambaram M., Radha V., Mohan V., Replication of recently described type 2 diabetes gene variants in a South Indian population. Metabolism 2010 59 12 1760 1766 2-s2.0-78549232589 10.1016/j.metabol.2010.04.024
101. Chauhan G., Spurgeon C. J., Tabassum R., Bhaskar S., Kulkarni S. R.,
102. Rees S. D., Hydrie M. Z. I., Shera A. S., Kumar S., O'Hare J. P., Barnett A. H., Basit A., Kelly M. A., Replication of 13 genome-wide association (GWA)-validated risk variants for type 2 diabetes in Pakistani populations. Diabetologia 2011 54 6 1368 1374 2-s2.0-80052517091 10.1007/s00125-011-2063-2
103. Ma L., Hanson R. L., Que L. N., Cali A. M. G., Fu M., Mack J. L., Infante A. M., Kobes S., Bogardus C., Shuldiner A. R., Baier L. J., Variants in ARHGEF11, a candidate gene for the linkage to type 2 diabetes on chromosome 1q, are nominally associated with insulin resistance and type 2 diabetes in Pima Indians. Diabetes 2007 56 5 1454 1459 2-s2.0-34248162419 10.2337/db06-0640
104. Ma L., Hanson R. L., Que L. N., Guo Y., Kobes S., Bogardus C., Baier L. J., PCLO variants are nominally associated with early-onset type 2 diabetes and insulin resistance in Pima Indians. Diabetes 2008 57 11 3156 3160 2-s2.0-58149333719 10.2337/db07-1800
105. Bian L., Hanson R. L., Muller Y. L., Ma L., Kobes S., Knowler W. C., Bogardus C., Baier L. J., Variants in ACAD10 are associated with type 2 diabetes, insulin resistance and lipid oxidation in Pima Indians. Diabetologia 2010 53 7 1349 1353 2-s2.0-77955657911 10.1007/s00125-010-1695-y
106. Bian L., Hanson R. L., Ossowski V., Wiedrich K., Mason C. C., Traurig M., Muller Y. L., Kobes S., Knowler W. C., Baier L. J., Bogardus C., Variants in ASK1 are associated with skeletal muscle ASK1 expression, in vivo insulin resistance, and type 2 diabetes in Pima Indians. Diabetes 2010 59 5 1276 1282 2-s2.0-77951784610 10.2337/db09-1700
107. Rong R., Hanson R. L., Ortiz D., Wiedrich C., Kobes S., Knowler W. C., Bogardus C., Baier L. J., Association analysis of variation in/near FTO, CDKAL1, SLC30A8, HHEX, EXT2, IGF2BP2, LOC387761, and CDKN2B with type 2 diabetes and related quantitative traits in Pima Indians. Diabetes 2009 58 2 478 488 2-s2.0-63249107785 10.2337/db08-0877
108. Hayes M. G., Pluzhnikov A., Miyake K., Sun Y., Ng M. C. Y., Roe C. A., Below J. E., Nicolae R. I., Konkashbaev A., Bell G. I., Cox N. J., Hanis C. L., Identification of type 2 diabetes genes in Mexican Americans through genome-wide association studies. Diabetes 2007 56 12 3033 3044 2-s2.0-36849081967 10.2337/db07-0482
109. Below J. E., Gamazon E. R., Morrison J. V., Konkashbaev A., Pluzhnikov A., McKeigue P. M., Parra E. J., Elbein S. C., Hallman D. M., Nicolae D. L., Bell G. I., Cruz M., Cox N. J., Hanis C. L., Genome-wide association and meta-analysis in populations from Starr County, Texas, and Mexico City identify type 2 diabetes susceptibility loci and enrichment for expression quantitative trait loci in top signals. Diabetologia 2011 54 8 2047 2055 2-s2.0-79960923810 10.1007/s00125-011-2188-3
110. Sequence variants in SLC16A11 are a common risk factor for type 2 diabetes in Mexico. Nature 2013 506 97 101 10.1038/nature12828
111. Lyssenko V., Nagorny C. L. F., Erdos M. R., Wierup N., Jonsson A., Spégel P., Bugliani M., Saxena R., Fex M., Pulizzi N., Isomaa B., Tuomi T., Nilsson P., Kuusisto J., Tuomilehto J., Boehnke M., Altshuler D., Sundler F., Eriksson J. G., Jackson A. U., Laakso M., Marchetti P., Watanabe R. M., Mulder H., Groop L., Common variant in MTNR1B associated with increased risk of type 2 diabetes and impaired early insulin secretion. Nature Genetics 2009 41 1 82 88 2-s2.0-58149175669 10.1038/ng.288
112. Boesgaard T. W., Grarup N., Jørgensen T., Borch-Johnsen K., Hansen T., Pedersen O., Variants at DGKB/TMEM195, ADRA2A, GLIS3 and C2CD4B loci are associated with reduced glucose-stimulated beta cell function in middle-aged Danish people. Diabetologia 2010 53 8 1647 1655 2-s2.0-77955509318 10.1007/s00125-010-1753-5
113. Nielsen T., Sparsø T., Grarup N., Jørgensen T., Pisinger C., Witte D. R., Hansen T., Pedersen O., Type 2 diabetes risk allele near CENTD2 is associated with decreased glucose-stimulated insulin release. Diabetologia 2011 54 5 1052 1056 2-s2.0-79954632738 10.1007/s00125-011-2054-3
114. Rees S. D., Hydrie M. Z. I., O'Hare J. P., Kumar S., Shera A. S., Basit A., Barnett A. H., Kelly M. A., Effects of 16 genetic variants on fasting glucose and type 2 diabetes in South Asians: ADCY5 and GLIS3 variants may predispose to type 2 diabetes. PLoS ONE 2011 6 9 2-s2.0-80052939674 10.1371/journal.pone.0024710 e24710
115. Boesgaard T. W., Gjesing A. P., Grarup N., Rutanen J., Jansson P.-A., Hribal M. L., Sesti G., Fritsche A., Stefan N., Staiger H., Häring H., Smith U., Laakso M., Pedersen O., Hansen T., Variant near ADAMTS9 known to associate with type 2 diabetes is related to insulin resistance in offspring of type 2 diabetes patients-EUGENE2 study. PLoS ONE 2009 4 9 2-s2.0-70349833653 10.1371/journal.pone.0007236 e7236
116. Anand A., Chada K., In vivo modulation of Hmgic reduces obesity. Nature Genetics 2000 24 4 377 380 2-s2.0-0034069653 10.1038/74207
117. Binh T. Q., Phuong P. T., Nhung B. T., Association of the common FTO -rs9939609 polymorphism with type 2 diabetes, independent of obesity-related traits in a Vietnamese population. Gene 2013 513 1 31 35 10.1016/j.gene.2012.10. 082
118. Xi B., Takeuchi F., Chandak G. R., Common polymorphism near the MC4R gene is associated with type 2 diabetes: data from a meta-analysis of 123, 373 individuals. Diabetologia 2012 55 10 2660 2666
119. Lyssenko V., Lupi R., Marchetti P., Del Guerra S., Orho-Melander M., Almgren P., Sjögren M., Ling C., Eriksson K.-F., Lethagen Å.-L., Mancarella R., Berglund G., Tuomi T., Nilsson P., del Prato S., Groop L., Mechanisms by which common variants in the TCF7L2 gene increase risk of type 2 diabetes. The Journal of Clinical Investigation 2007 117 8 2155 2163 2-s2.0-34547702501 10.1172/JCI30706
120. Villareal D. T., Robertson H., Bell G. I., Patterson B. W., Tran H., Wice B., Polonsky K. S., TCF7L2 variant rs7903146 affects the risk of type 2 diabetes by modulating incretin action. Diabetes 2010 59 2 479 485 2-s2.0-77449099615 10.2337/db09-1169
121. le Bacquer O., Kerr-Conte J., Gargani S., TCF7L2 rs7903146 impairs islet function and morphology in non-diabetic individuals. Diabetologia 2012 55 10 2677 2681 10.1007/s00125-012-2660-8
122. Takeda Y., Fujita Y., Honjo J., Yanagimachi T., Sakagami H., Takiyama Y., Makino Y., Abiko A., Kieffer T. J., Haneda M., Reduction of both β cell death and alpha cell proliferation by dipeptidyl peptidase-4 inhibition in a streptozotocin-induced model of diabetes in mice. Diabetologia 2012 55 2 404 412 2-s2.0-84856711643 10.1007/s00125-011-2365-4
123. Yoon K. H., Ko S. H., Cho J. H., Selective β -cell loss and α -cell expansion in patients with type 2 diabetes mellitus in Korea. The Journal of Clinical Endocrinology & Metabolism 2003 88 5 2300 2308 10.1210/jc.2002-020735
124. Kirkpatrick C. L., Marchetti P., Purrello F., Piro S., Bugliani M., Bosco D., de Koning E. J. P., Engelse M. A., Kerr-Conte J., Pattou F., Wollheim C. B., Type 2 diabetes susceptibility gene expression in normal or diabetic sorted human alpha and beta cells: correlations with age or BMI of islet donors. PLoS ONE 2010 5 6 e11053 2-s2.0-77956197973 10.1371/journal.pone.0011053
125. Korinek V., Barker N., Moerer P., van Donselaar E., Huls G., Peters P. J., Clevers H., Depletion of epithelial stem-cell compartments in the small intestine of mice lacking Tcf-4. Nature Genetics 1998 19 4 379 383 2-s2.0-0031848068 10.1038/1270
126. Ip W., Chiang Y. T., Jin T., The involvement of the Wnt signaling pathway and TCF7L2 in diabetes mellitus: the current understanding, dispute, and perspective. Cell & Bioscience 2012 2 1, article 28 10.1186/2045-3701-2-28
127. Dessimoz J., Bonnard C., Huelsken J., Grapin-Botton A., Pancreas-specific deletion of β -catenin reveals Wnt-dependent and Wnt-independent functions during development. Current Biology 2005 15 18 1677 1683 2-s2.0-24944487996 10.1016/j.cub.2005.08.037
128. Murtaugh L. C., Law A. C., Dor Y., Melton D. A., β -catenin is essential for pancreatic acinar but not islet development. Development 2005 132 21 4663 4674 2-s2.0-28044449357 10.1242/dev.02063
129. Papadopoulou S., Edlund H., Attenuated Wnt signaling perturbs pancreatic growth but not pancreatic function. Diabetes 2005 54 10 2844 2851 2-s2.0-25844530871 10.2337/diabetes.54.10.2844
130. Heiser P. W., Lau J., Taketo M. M., Herrera P. L., Hebrok M., Stabilization of β -catenin impacts pancreas growth. Development 2006 133 10 2023 2032 2-s2.0-33745084564 10.1242/dev.02366
131. Heller R. S., Dichmann D. S., Jensen J., Miller C., Wong G., Madsen O. D., Serup P., Expression patterns of Wnts, Frizzleds, sFRPs, and misexpression in transgenic mice suggesting a role for Wnts in pancreas and foregut pattern formation. Developmental Dynamics 2002 225 3 260 270 2-s2.0-0036842027 10.1002/dvdy.10157
132. Rulifson I. C., Karnik S. K., Heiser P. W., Ten Berge D., Chen H., Gu X., Taketo M. M., Nusse R., Hebrok M., Kim S. K., Wnt signaling regulates pancreatic β cell proliferation. Proceedings of the National Academy of Sciences of the United States of America 2007 104 15 6247 6252 2-s2.0-34547516561 10.1073/pnas.0701509104
133. Boj S. F., van Es J. H., Huch M., Diabetes risk gene and Wnt effector TCF7L2 /TCF4 controls hepatic response to perinatal and adult metabolic demand. Cell 2012 151 7 1595 1607 10.1016/j.cell.2012.10.053
134. Chimienti F., Favier A., Seve M., ZnT-8, a pancreatic β -cell-specific zinc transporter. Biometals 2005 18 4 313 317 2-s2.0-24744451161 10.1007/s10534-005-3687-9
135. Tamaki M., Fujitani Y., Uchida T., Hirose T., Kawamori R., Watada H., Downregulation of ZnT8 expression in pancreatic β -cells of diabetic mice. Islets 2009 1 2 124 128 2-s2.0-77955518148
136. Pound L. D., Sarkar S. A., Benninger R. K. P., Wang Y., Suwanichkul A., Shadoan M. K., Printz R. L., Oeser J. K., Lee C. E., Piston D. W., McGuinness O. P., Hutton J. C., Powell D. R., O'Brien R. M., Deletion of the mouse Slc30a8 gene encoding zinc transporter-8 results in impaired insulin secretion. Biochemical Journal 2009 421 3 371 376 2-s2.0-69249226366 10.1042/BJ20090530
137. Tamaki M., Fujitani Y., Hara A., The diabetes-susceptible gene SLC30A8 /ZnT8 regulates hepatic insulin clearance. The Journal of Clinical Investigation 2013 123 10 4513 4524 10.1172/JCI68807
138. Chimienti F., Devergnas S., Pattou F., Schult F., Garcia-Cuenca R., Vandewalle B., Kerr-Conte J., van Lommel L., Grunwald D., Favier A., Seve M., In vivo expression and functional characterization of the zinc transporter ZnT8 in glucose-induced insulin secretion. Journal of Cell Science 2006 119 20 4199 4206 2-s2.0-33751183948 10.1242/jcs.03164
139. Pound L. D., Hang Y., Sarkar S. A., Wang Y., Milam L. A., Oeser J. K., Printz R. L., Lee C. E., Stein R., Hutton J. C., O'Brien R. M., The pancreatic islet β -cell-enriched transcription factor Pdx-1 regulates Slc30a8 gene transcription through an intronic enhancer. Biochemical Journal 2011 433 1 95 105 2-s2.0-79551470998 10.1042/BJ20101488
140. Qi Q., Hu F. B., Genetics of type 2 diabetes in European populations. Journal of Diabetes 2012 4 3 203 212 10.1111/j.1753-0407.2012.00224.x
141. Imamura M., Shigemizu D., Tsunoda T., Assessing the clinical utility of a genetic risk score constructed using 49 susceptibility alleles for type 2 diabetes in a Japanese population. The Journal of Clinical Endocrinology & Metabolism 2013 98 10 1667 1673 10.1210/jc.2012-3791
142. Cooke J. N., Ng M. C. Y., Palmer N. D., Hester J. M., Freedman B. I., Langefeld C. D., An S. S., Bowden D. W., Genetic risk assessment of type 2 diabetes-associated polymorphisms in African Americans. Diabetes Care 2012 35 2 287 292 2-s2.0-84859068424 10.2337/dc11-0957
143. Iwata M., Maeda S., Kamura Y., Genetic risk score constructed using 14 susceptibility alleles for type 2 diabetes is associated with the early onset of diabetes and may predict the future requirement of insulin injections among Japanese individuals. Diabetes Care 2012 35 8 1763 1770
144. Talmud P. J., Hingorani A. D., Cooper J. A., Marmot M. G., Brunner E. J., Kumari M., Kivimäki M., Humphries S. E., Utility of genetic and non-genetic risk factors in prediction of type 2 diabetes: Whitehall II prospective cohort study. British Medical Journal 2010 340 b4838 10.1136/bmj.b4838
145. de Miguel-Yanes J. M., Shrader P., Pencina M. J., Fox C. S., Manning A. K., Grant R. W., Dupuis J., Florez J. C., D'Agostino R. B., Cupples L. A., Meigs J. B., Genetic risk reclassification for type 2 diabetes by age below or above 50 years using 40 type 2 diabetes risk single nucleotide polymorphisms. Diabetes Care 2011 34 1 121 125 2-s2.0-79951715822 10.2337/dc10-1265
146. Cornelis M. C., Hu F. B., Gene-environment interactions in the development of type 2 diabetes: recent progress and continuing challenges. Annual Review of Nutrition 2012 32 245 259
147. Wang L., McLeod H. L., Weinshilboum R. M., Genomics and drug response. The New England Journal of Medicine 2011 364 12 1144 1153 2-s2.0-79953174333 10.1056/NEJMra1010600
148. Mannino G. C., Sesti G., Individualized therapy for type 2 diabetes: clinical implications of pharmacogenetic data. Molecular Diagnosis & Therapy 2012 16 5 285 302
149. Xu H., Murray M., McLachlan A. J., Influence of genetic polymorphisms on the pharmacokinetics and pharmacodynamics of sulfonylurea drugs. Current Drug Metabolism 2009 10 6 643 658 2-s2.0-70450133969 10.2174/138920009789375388
150. Surendiran A., Pradhan S. C., Agrawal A., Subrahmanyam D. K. S., Rajan S., Anichavezhi D., Adithan C., Influence of CYP2C9 gene polymorphisms on response to glibenclamide in type 2 diabetes mellitus patients. European Journal of Clinical Pharmacology 2011 67 8 797 801 2-s2.0-79960965105 10.1007/s00228-011-1013-8
151. Rafiq M., Flanagan S. E., Patch A.-M., Shields B. M., Ellard S., Hattersley A. T., Batra C., Bruining J., Carson D., Codner E., Cummings E., Curran J., Davis E., Deiss D., Herr M., Hussain K., Legault L., Malecki M., Paskova M., Pearson E., Rodda C., Rothenbuhler A., Sanchez J., Shield J., Stanca R.-M., Van Der Meulen J., Effective treatment with oral sulfonylureas in patients with diabetes due to sulfonylurea receptor 1 (SUR1) mutations. Diabetes Care 2008 31 2 204 209 2-s2.0-38949177444 10.2337/dc07-1785
152. Feng Y., Mao G., Ren X., Xing H., Tang G., Li Q., Li X., Sun L., Yang J., Ma W., Wang X., Xu X., Ser1369Ala variant in sulfonylurea receptor gene ABCC8 is associated with antidiabetic efficacy of gliclazide in Chinese type 2 diabetic patients. Diabetes Care 2008 31 10 1939 1944 2-s2.0-56149106823 10.2337/dc07-2248
153. Pearson E. R., Donnelly L. A., Kimber C., Whitley A., Doney A. S. F., McCarthy M. I., Hattersley A. T., Morris A. D., Palmer C. N. A., Variation in TCF7L2 influences therapeutic response to sulfonylureas: a GoDARTs study. Diabetes 2007 56 8 2178 2182 2-s2.0-34547585382 10.2337/db07-0440
154. García-Escalante M. G., Suárez-Solís V. M., López-Ávila M. T. D. J., Pinto-Escalante D. D. C., Laviada-Molina H., Effect of the Gly972Arg, SNP43 and Pro12Ala polymorphisms of the genes IRS1, CAPN10 and PPARG2 on secondary failure to sulphonylurea and metformin in patients with type 2 diabetes in Yucatán, México. Investigacion Clinica 2009 50 1 65 76 2-s2.0-67649088187
155. Becker M. L., Aarnoudse A.-J., Newton-Cheh C., Hofman A., Witteman J. C. M., Uitterlinden A. G., Visser L. E., Stricker B. H. C., Common variation in the NOS1AP gene is associated with reduced glucose-lowering effect and with increased mortality in users of sulfonylurea. Pharmacogenetics and Genomics 2008 18 7 591 597 2-s2.0-53049096127 10.1097/FPC.0b013e328300e8c5
156. Seeringer A., Parmar S., Fischer A., Altissimo B., Zondler L., Lebedeva E., Pitterle K., Roots I., Kirchheiner J., Genetic variants of the insulin receptor substrate-1 are influencing the therapeutic efficacy of oral antidiabetics. Diabetes, Obesity and Metabolism 2010 12 12 1106 1112 2-s2.0-77958580853 10.1111/j.1463-1326.2010.01301.x
157. 972 variant in insulin receptor substrate-1 is associated with an increased risk of secondary failure to sulfonylurea in patients with type 2 diabetes. Diabetes Care 2004 27 6 1394 1398 2-s2.0-2542460652 10.2337/diacare.27.6.1394
158. Pearson E. R., Flechtner I., Njølstad P. R., Malecki M. T., Flanagan S. E., Larkin B., Ashcroft F. M., Klimes I., Codner E., Iotova V., Slingerland A. S., Shield J., Robert J.-J., Holst J. J., Clark P. M., Ellard S., Søvik O., Polak M., Hattersley A. T., Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations. The New England Journal of Medicine 2006 355 5 467 477 2-s2.0-33746686369 10.1056/NEJMoa061759
159. Shu Y., Sheardown S. A., Brown C., Owen R. P., Zhang S., Castro R. A., Ianculescu A. G., Yue L., Lo J. C., Burchard E. G., Brett C. M., Giacomini K. M., Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. The Journal of Clinical Investigation 2007 117 5 1422 1431 2-s2.0-34248156160 10.1172/JCI30558
160. Tzvetkov M. V., Vormfelde S. V., Balen D., Meineke I., Schmidt T., Sehrt D., Sabolić I., Koepsell H., Brockmöller J., The effects of genetic polymorphisms in the organic cation transporters OCT1, OCT2, and OCT3 on the renal clearance of metformin. Clinical Pharmacology & Therapeutics 2009 86 3 299 306 2-s2.0-69449098951 10.1038/clpt.2009.92
161. Becker M. L., Visser L. E., van Schaik R. H. N., Hofman A., Uitterlinden A. G., Stricker B. H. C., Genetic variation in the organic cation transporter 1 is associated with metformin response in patients with diabetes mellitus. Pharmacogenomics Journal 2009 9 4 242 247 2-s2.0-67849116869 10.1038/tpj.2009.15
162. Christensen M. M. H., Brasch-Andersen C., Green H., Nielsen F., Damkier P., Beck-Nielsen H., Brosen K., The pharmacogenetics of metformin and its impact on plasma metformin steady-state levels and glycosylated hemoglobin A1c. Pharmacogenetics and Genomics 2011 21 12 837 850 2-s2.0-81055140250 10.1097/FPC.0b013e32834c0010
163. Song I. S., Shin H. J., Shim E. J., Jung I. S., Kim W. Y., Shon J. H., Shin J. G., Genetic variants of the organic cation transporter 2 influence the disposition of metformin. Clinical Pharmacology & Therapeutics 2008 84 5 559 562 2-s2.0-54249106729 10.1038/clpt.2008.61
164. Becker M. L., Visser L. E., van Schaik R. H. N., Hofman A., Uitterlinden A. G., Stricker B. H. C., Genetic variation in the multidrug and toxin extrusion 1 transporter protein influences the glucose-lowering effect of metformin in patients with diabetes: a preliminary study. Diabetes 2009 58 3 745 749 2-s2.0-62749133967 10.2337/db08-1028
165. Jablonski K. A., McAteer J. B., de Bakker P. I. W., Franks P. W., Pollin T. I., Hanson R. L., Saxena R., Fowler S., Shuldiner A. R., Knowler W. C., Altshuler D., Florez J. C., Common variants in 40 genes assessed for diabetes incidence and response to metformin and lifestyle intervention in the diabetes prevention program. Diabetes 2010 59 10 2672 2681 2-s2.0-77957601724 10.2337/db10-0543
166. Choi J. H., Yee S. W., Ramirez A. H., Morrissey K. M., Jang G. H., Joski P. J., Mefford J. A., Hesselson S. E., Schlessinger A., Jenkins G., Castro R. A., Johns S. J., Stryke D., Sali A., Ferrin T. E., Witte J. S., Kwok P.-Y., Roden D. M., Wilke R. A., McCarty C. A., Davis R. L., Giacomini K. M., A common 5′-UTR variant in MATE2-K is associated with poor response to metformin. Clinical Pharmacology & Therapeutics 2011 90 5 674 684 2-s2.0-80054970528 10.1038/clpt.2011.165
167. Zhou K., Bellenguez C., Spencer C. C. A., Bennett A. J., Coleman R. L., Tavendale R., Hawley S. A., Donnelly L. A., Schofield C., Groves C. J., Burch L., Carr F., Strange A., Freeman C., Blackwell J. M., Bramon E., Brown M. A., Casas J. P., Corvin A., Craddock N., Deloukas P., Dronov S., Duncanson A., Edkins S., Gray E., Hunt S., Jankowski J., Langford C., Markus H. S., Mathew C. G., Plomin R., Rautanen A., Sawcer S. J., Samani N. J., Trembath R., Viswanathan A. C., Wood N. W., Harries L. W., Hattersley A. T., Doney A. S. F., Colhoun H., Morris A. D., Sutherland C., Hardie D. G., Peltonen L., McCarthy M. I., Holman R. R., Palmer C. N. A., Donnelly P., Pearson E. R., Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes. Nature Genetics 2011 43 2 117 120 2-s2.0-79251612707 10.1038/ng.735
168. Kirchheiner J., Roots I., Goldammer M., Rosenkranz B., Brockmöller J., Effect of genetic polymorphisms in cytochrome P450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance. Clinical Pharmacokinetics 2005 44 12 1209 1225 2-s2.0-29244482237 10.2165/00003088- 200544120-00002
169. Cheng Y., Wang G., Zhang W., Effect of CYP2C9 and SLCO1B1 polymorphisms on the pharmacokinetics and pharmacodynamics of nateglinide in healthy Chinese male volunteers. European Journal of Clinical Pharmacology 2013 69 3 407 413 10.1007/s00228-012-1364-9
170. Zhang W., He Y.-J., Han C.-T., Liu Z.-Q., Li Q., Fan L., Tan Z.-R., Zhang W.-X., Yu B.-N., Wang D., Hu D.-L., Zhou H.-H., Effect of SLCO1B1 genetic polymorphism on the pharmacokinetics of nateglinide. British Journal of Clinical Pharmacology 2006 62 5 567 572 2-s2.0-33749985427 10.1111/j.1365-2125.2006. 02686.x
171. Huang Q., Yin J.-Y., Dai X.-P., Wu J., Chen X., Deng C.-S., Yu M., Gong Z.-C., Zhou H.-H., Liu Z.-Q., Association analysis of SLC30A8 rs13266634 and rs16889462 polymorphisms with type 2 diabetes mellitus and repaglinide response in Chinese patients. European Journal of Clinical Pharmacology 2010 66 12 1207 1215 2-s2.0-78649328506 10.1007/s00228-010-0882-6
172. Xiang Q., Cui Y. M., Zhao X., Yan L., Zhou Y., The influence of MDR1 G2677T/A genetic polymorphisms on the pharmacokinetics of repaglinide in healthy Chinese volunteers. Pharmacology 2012 89 1-2 105 110 2-s2.0-84857712798 10.1159/000336345
173. Dai X.-P., Huang Q., Yin J.-Y., Guo Y., Gong Z.-C., Lei M.-X., Jiang T.-J., Zhou H.-H., Liu Z.-Q., KCNQ1 gene polymorphisms are associated with the therapeutic efficacy of repaglinide in Chinese type 2 diabetic patients. Clinical and Experimental Pharmacology and Physiology 2012 39 5 462 468 2-s2.0-84860234285 10.1111/j.1440-1681.2012.05701.x
174. Sheng F.-F., Dai X.-P., Qu J., Lei G.-H., Lu H.-B., Wu J., Xu X.-J., Pei Q., Dong M., Liu Y.-Z., Zhou H.-H., Liu Z.-Q., NAMPT-3186C/T polymorphism affects repaglinide response in Chinese patients with type 2 diabetes mellitus. Clinical and Experimental Pharmacology and Physiology 2011 38 8 550 554 2-s2.0-79960729009 10.1111/j.1440-1681.2011.05548.x
175. Takane H., Genetic polymorphisms of SLCO1B1 for drug pharmacokinetics and its clinical implications. Yakugaku Zasshi 2011 131 11 1589 1594 2-s2.0-80455129101 10.1248/yakushi.131.1589
176. He J., Qiu Z., Li N., Yu Y., Lu Y., Han D., Li T., Zhao D., Sun W., Fang F., Zheng J., Fan H., Chen X., Effects of SLCO1B1 polymorphisms on the pharmacokinetics and pharmacodynamics of repaglinide in healthy Chinese volunteers. European Journal of Clinical Pharmacology 2011 67 7 701 707 2-s2.0-79959753093 10.1007/s00228-011-0994-7
177. Mizushige K., Tsuji T., Noma T., Pioglitazone: cardiovascular effects in prediabetic patients. Cardiovascular Drug Reviews 2002 20 4 329 340 2-s2.0-0036959197
178. Kang E. S., Park S. Y., Kim H. J., Chul S. K., Chul W. A., Bong S. C., Sung K. L., Chung M. N., Hyun C. L., Effects of Pro12Ala polymorphism of peroxisome proliferator-activated receptor γ 2 gene on rosiglitazone response in type 2 diabetes. Clinical Pharmacology & Therapeutics 2005 78 2 202 208 2-s2.0-23444457610 10.1016/j.clpt.2005.04.013
179. Zhang K.-H., Huang Q., Dai X.-P., Yin J.-Y., Zhang W., Zhou G., Zhou H.-H., Liu Z.-Q., Effects of the peroxisome proliferator activated receptor- γ coactivator-1 α (PGC -1 α) Thr394Thr and Gly482Ser polymorphisms on rosiglitazone response in Chinese patients with type 2 diabetes mellitus. The Journal of Clinical Pharmacology 2010 50 9 1022 1030 2-s2.0-78650571748 10.1177/0091270009355159
180. Makino H., Shimizu I., Murao S., Kondo S., Tabara Y., Fujiyama M., Fujii Y., Takada Y., Nakai K., Izumi K., Ohashi J., Kawamura R., Yamauchi J., Takata Y., Nishida W., Hashiramoto M., Onuma H., Osawa H., A pilot study suggests that the G/G genotype of resistin single nucleotide polymorphism at -420 may be an independent predictor of a reduction in fasting plasma glucose and insulin resistance by pioglitazone in type 2 diabetes. Endocrine Journal 2009 56 9 1049 1058 2-s2.0-74749093514 10.1507/endocrj.K08E-320
181. Sun H., Gong Z.-C., Yin J.-Y., Liu H.-L., Liu Y.-Z., Guo Z.-W., Zhou H.-H., Wu J., Liu Z.-Q., The association of adiponectin allele 45T/G and-11377C/G polymorphisms with type 2 diabetes and rosiglitazone response in Chinese patients. British Journal of Clinical Pharmacology 2008 65 6 917 926 2-s2.0-43549096615 10.1111/j.1365-2125.2008.03145.x
182. Liu H.-L., Lin Y.-G., Wu J., Sun H., Gong Z.-C., Hu P.-C., Yin J.-Y., Zhang W., Wang D., Zhou H.-H., Liu Z.-Q., Impact of genetic polymorphisms of leptin and TNF- α on rosiglitazone response in Chinese patients with type 2 diabetes. European Journal of Clinical Pharmacology 2008 64 7 663 671 2-s2.0-44449136358 10.1007/s00228-008-0483-9
183. Kirchheiner J., Thomas S., Bauer S., Tomalik-Scharte D., Hering U., Doroshyenko O., Jetter A., Stehle S., Tsahuridu M., Meineke I., Brockmöller J., Fuhr U., Pharmacokinetics and pharmacodynamics of rosiglitazone in relation to CYP2C8 genotype. Clinical Pharmacology & Therapeutics 2006 80 6 657 667 2-s2.0-33845515897 10.1016/j.clpt.2006.09.008